Open Payments

Ascension St John Hospital

Type
Teaching hospital
Where
Detroit, MI
Medicare CCN
230165
Received
$873,492 in 196 records, 2024 ($38,787 general, $834,704 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment20$38,787
2024Research payment176$834,704

By company

CompanyRecordsAmountYears
PFIZER INC.47$381,8962024
Medtronic, Inc.69$232,4122024
Genentech, Inc.11$75,3962024
Genetesis, Inc.6$52,0692024
Impulse Dynamics (USA) Inc.20$50,9972024
Eli Lilly and Company2$15,0602024
Penumbra, Inc.10$10,6602024
Biogen, Inc.1$10,5152024
ERBE USA Inc2$7,0002024
Boston Scientific Corporation2$7,0002024
Regeneron Healthcare Solutions, Inc.3$6,0002024
ABBVIE INC.2$4,0002024
Takeda Pharmaceuticals U.S.A., Inc.2$4,0002024
Olympus Corporation of the Americas1$4,0002024
Gilead Sciences, Inc.3$2,6832024
ACUMED LLC1$2,0002024
Olympus America Inc.2$2,0002024
Endologix LLC1$1,9502024
BIOTRONIK INC.7$1,5622024
Celgene Corporation1$1,5002024
AngioDynamics, Inc.1$5772024
Baxter Healthcare1$1592024
Abbott Laboratories1$502024

By nature of payment

NatureRecordsAmount
Research payment176$834,704
Grant7$19,000
Space rental or facility fees (teaching hospital only)9$12,050
Honoraria1$5,000
Education1$2,000
Long term medical supply or device loan1$577
Debt forgiveness1$159

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-31PFIZER INC.$22,235Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-12-18Medtronic, Inc.$19,599Research paymentCash or cash equivalentSYMPLICITY G3 Device, Renal Denervation SystemSPYRAL AFFIRM2024
2024-12-16Medtronic, Inc.$1,064Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2024
2024-12-16Medtronic, Inc.$1,064Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2024
2024-12-11Medtronic, Inc.$6,163Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-12-09Genentech, Inc.$24,150Research paymentCash or cash equivalentTecentriq Biological, BioOncologyA PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TIRA PLUS ATEZO IN ADJUVANT NSCLC2024
2024-12-09Genentech, Inc.$18,950Research paymentCash or cash equivalentTecentriq Biological, BioOncologyA PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TIRA PLUS ATEZO IN ADJUVANT NSCLC2024
2024-12-05PFIZER INC.$25,836Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-12-03Medtronic, Inc.$1,625Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsOptimize Pro2024
2024-12-03Medtronic, Inc.$1,625Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsOptimize Pro2024
2024-11-27Impulse Dynamics (USA) Inc.$75Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DevicePost Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy2024
2024-11-13Penumbra, Inc.$300Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2024
2024-11-08PFIZER INC.$7,606Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-11-08Eli Lilly and Company$9Research paymentIn-kind items and servicesSTUDY OF LOXO-305 VERSUS INVESTIGATOR'S CHOICE (IDELAR OR BR) IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LE2024
2024-11-06Celgene Corporation$1,500Research paymentCash or cash equivalentCelgene Connect Myeloid Disease Registry2024
2024-11-06Impulse Dynamics (USA) Inc.$300Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DeviceAssessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer)2024
2024-10-22PFIZER INC.$1,413Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2024
2024-10-21Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-10-21Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-10-19PFIZER INC.$11,784Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-10-10Medtronic, Inc.$1,860Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2024
2024-10-10Medtronic, Inc.$1,860Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2024
2024-10-10Medtronic, Inc.$1,791Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2024
2024-10-10Medtronic, Inc.$1,791Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2024
2024-10-08PFIZER INC.$350Research paymentCash or cash equivalentAN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL 2024
2024-09-30Impulse Dynamics (USA) Inc.$1,469Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DeviceAssessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer)2024
2024-09-30Impulse Dynamics (USA) Inc.$200Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DevicePost Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy2024
2024-09-28PFIZER INC.$11,726Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-09-26Medtronic, Inc.$10,500Research paymentCash or cash equivalentSYMPLICITY G3 Device, Renal Denervation SystemSPYRAL AFFIRM2024
2024-09-26Medtronic, Inc.$1,000Research paymentCash or cash equivalentSYMPLICITY G3 Device, Renal Denervation SystemSPYRAL AFFIRM2024
2024-09-25Medtronic, Inc.$56,981Research paymentCash or cash equivalentSYMPLICITY G3 Device, Renal Denervation SystemSPYRAL AFFIRM2024
2024-09-19Medtronic, Inc.$3,108Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-09-19Medtronic, Inc.$3,108Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-09-17Abbott Laboratories$50Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-09-12Medtronic, Inc.$2,419Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2024
2024-09-12Medtronic, Inc.$2,419Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2024
2024-09-09Medtronic, Inc.$13,000Research paymentCash or cash equivalentSYMPLICITY G3 Device, Renal Denervation SystemSPYRAL AFFIRM2024
2024-09-06Medtronic, Inc.$875Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-09-06Medtronic, Inc.$875Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-09-04PFIZER INC.$27,890Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-08-29Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-08-29Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-08-27PFIZER INC.$3,500Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREF2024
2024-08-23Impulse Dynamics (USA) Inc.$124Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DeviceAssessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer)2024
2024-08-22PFIZER INC.$4,825Research paymentCash or cash equivalentAN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL 2024
2024-08-21Penumbra, Inc.$96Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2024
2024-08-20Genetesis, Inc.$14,510Research paymentCash or cash equivalentCardioFlux Device, Cardiovascular DiagnosticMCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)2024
2024-08-14PFIZER INC.$6,145Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2024
2024-08-14Genentech, Inc.$4,745Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2024
2024-08-13Impulse Dynamics (USA) Inc.$869Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DeviceAssessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer)2024
2024-08-08Medtronic, Inc.$1,000Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-08-08Medtronic, Inc.$1,000Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-08-08Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2024
2024-08-08Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2024
2024-08-07Impulse Dynamics (USA) Inc.$220Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DeviceAssessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer)2024
2024-08-05Medtronic, Inc.$200Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2024
2024-08-05Medtronic, Inc.$200Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2024
2024-08-01Genentech, Inc.$5,640Research paymentCash or cash equivalentMorningSun2024
2024-07-26PFIZER INC.$1,616Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2024
2024-07-24PFIZER INC.$960Research paymentCash or cash equivalentAN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL 2024
2024-07-22Medtronic, Inc.$150Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-07-19Impulse Dynamics (USA) Inc.$500Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DevicePost Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy2024
2024-07-17Medtronic, Inc.$840Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2024
2024-07-17Medtronic, Inc.$840Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2024
2024-07-16PFIZER INC.$3,248Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2024
2024-07-16Medtronic, Inc.$1,267Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2024
2024-07-16Medtronic, Inc.$1,267Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2024
2024-07-16Medtronic, Inc.$875Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2024
2024-07-16Medtronic, Inc.$875Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2024
2024-07-15Penumbra, Inc.$1,806Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2024
2024-07-15Penumbra, Inc.$953Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2024
2024-07-11PFIZER INC.$18,293Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-07-11Genetesis, Inc.$1,463Research paymentCash or cash equivalentCardioFlux Device, Cardiovascular DiagnosticMCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR (Micro(T))2024
2024-07-09Gilead Sciences, Inc.$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-07-09Gilead Sciences, Inc.$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-06-28PFIZER INC.$1,897Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2024
2024-06-26PFIZER INC.$632Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2024
2024-06-13Gilead Sciences, Inc.$683Research paymentCash or cash equivalentSunlenca Drug, HIVA Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib2024
2024-06-11Impulse Dynamics (USA) Inc.$1,833Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DeviceAssessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer)2024
2024-06-06Medtronic, Inc.$745Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2024
2024-06-06Medtronic, Inc.$745Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2024
2024-06-06PFIZER INC.$117Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2024
2024-06-05Impulse Dynamics (USA) Inc.$5,250Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DeviceAssessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer)2024
2024-06-05Impulse Dynamics (USA) Inc.$2,750Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DevicePost Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy2024
2024-06-05Genentech, Inc.$1,500Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2024
2024-06-05Genentech, Inc.$1,500Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2024
2024-06-04Genetesis, Inc.$14,483Research paymentCash or cash equivalentCardioFlux Device, Cardiovascular DiagnosticMCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR (Micro(T))2024
2024-06-04PFIZER INC.$6,590Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-06-04ERBE USA Inc$5,000HonorariaCash or cash equivalentVio3 APC3 Device, ELECTROSURGICAL2024
2024-06-01PFIZER INC.$6,144Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2024
2024-05-23Medtronic, Inc.$20,167Research paymentCash or cash equivalentSYMPLICITY G3 Device, Renal Denervation SystemSPYRAL AFFIRM2024
2024-05-21Medtronic, Inc.$36,865Research paymentCash or cash equivalentSYMPLICITY G3 Device, Renal Denervation SystemSPYRAL AFFIRM2024
2024-05-21Baxter Healthcare$159Debt forgivenessIn-kind items and services2024
2024-05-17Genetesis, Inc.$8,128Research paymentCash or cash equivalentCardioFlux Device, Cardiovascular DiagnosticMCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR (Micro(T))2024
2024-05-16Impulse Dynamics (USA) Inc.$2,979Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DeviceAssessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer)2024
2024-05-15Penumbra, Inc.$138Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2024
2024-05-06Genetesis, Inc.$3,783Research paymentCash or cash equivalentCardioFlux Device, Cardiovascular DiagnosticMCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR (Micro(T))2024
2024-05-04PFIZER INC.$1,375Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-05-04PFIZER INC.$1,226Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2024
2024-05-02Olympus Corporation of the Americas$4,000GrantCash or cash equivalent2024
2024-04-26PFIZER INC.$5,686Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-04-26PFIZER INC.$4,660Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2024
2024-04-25PFIZER INC.$4,330Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2024
2024-04-23Penumbra, Inc.$250Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2024
2024-04-18BIOTRONIK INC.$250Research paymentCash or cash equivalentSiello Device, Cardiology/Vascular DiseasesSIELLO2024
2024-04-18BIOTRONIK INC.$250Research paymentCash or cash equivalentSiello Device, Cardiology/Vascular DiseasesSIELLO2024
2024-04-18BIOTRONIK INC.$212Research paymentCash or cash equivalentProtego S 65 Device, Cardiology/Vascular DiseasesProtego DF42024
2024-04-18BIOTRONIK INC.$212Research paymentCash or cash equivalentProtego S 65 Device, Cardiology/Vascular DiseasesProtego DF42024
2024-04-18BIOTRONIK INC.$212Research paymentCash or cash equivalentSiello Device, Cardiology/Vascular DiseasesSIELLO2024
2024-04-18BIOTRONIK INC.$212Research paymentCash or cash equivalentSiello Device, Cardiology/Vascular DiseasesSIELLO2024
2024-04-18BIOTRONIK INC.$212Research paymentCash or cash equivalentProtego S 65 Device, Cardiology/Vascular DiseasesProtego DF42024
2024-04-17Impulse Dynamics (USA) Inc.$3,684Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DeviceAssessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer)2024
2024-04-17Genentech, Inc.$2,819Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2024
2024-04-17Takeda Pharmaceuticals U.S.A., Inc.$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-04-17Impulse Dynamics (USA) Inc.$75Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DevicePost Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy2024
2024-04-12Impulse Dynamics (USA) Inc.$19,200Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DeviceAssessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer)2024
2024-04-12Boston Scientific Corporation$5,000GrantCash or cash equivalent Device, General - Therapies_ENDO2024
2024-04-12Boston Scientific Corporation$2,000GrantIn-kind items and services Device, General - Therapies_ENDO2024
2024-04-11Medtronic, Inc.$225Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2024
2024-04-11Medtronic, Inc.$225Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2024
2024-04-06ERBE USA Inc$2,000EducationCash or cash equivalentVio3 APC3 Device, Gastroenterology2024
2024-04-05PFIZER INC.$6,590Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-04-05PFIZER INC.$772Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2024
2024-04-03Medtronic, Inc.$605Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2024
2024-04-03Medtronic, Inc.$605Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2024
2024-04-03Genentech, Inc.$440Research paymentCash or cash equivalentTNKase Biological, Metabolism & Primary CareTenecteplase in stroke patients between 4 5 and 24 hours2024
2024-04-02Medtronic, Inc.$1,388Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-04-02Medtronic, Inc.$1,388Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-04-02Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-04-02Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-03-29PFIZER INC.$2,373Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2024
2024-03-29Penumbra, Inc.$250Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2024
2024-03-28PFIZER INC.$2,122Research paymentCash or cash equivalentAN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL 2024
2024-03-27Penumbra, Inc.$2,500Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2024
2024-03-26PFIZER INC.$5,886Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-03-26PFIZER INC.$3,028Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2024
2024-03-25Takeda Pharmaceuticals U.S.A., Inc.$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-03-22Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2024
2024-03-22Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2024
2024-03-21Regeneron Healthcare Solutions, Inc.$2,000GrantCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY2024
2024-03-21Regeneron Healthcare Solutions, Inc.$2,000GrantCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY2024
2024-03-21Regeneron Healthcare Solutions, Inc.$2,000GrantCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY2024
2024-03-20Olympus America Inc.$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentHANAROSTENT Biliary (NNN) Device, Endotherapy2024
2024-03-20Olympus America Inc.$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentHANAROSTENT Biliary (NNN) Device, Endotherapy2024
2024-03-15PFIZER INC.$1,633Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2024
2024-03-15Medtronic, Inc.$440Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2024
2024-03-15Medtronic, Inc.$440Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2024
2024-03-14Penumbra, Inc.$2,876Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2024
2024-03-13Biogen, Inc.$10,515Research paymentCash or cash equivalentRandomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Sa2024
2024-03-13ACUMED LLC$2,000GrantCash or cash equivalent2024
2024-03-06PFIZER INC.$31,187Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2024
2024-03-06PFIZER INC.$14,647Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-03-01Genetesis, Inc.$9,700Research paymentCash or cash equivalentCardioFlux Device, Cardiovascular DiagnosticMCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR (Micro(T))2024
2024-02-28ABBVIE INC.$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentLINZESS Drug, GASTROENTEROLOGY2024
2024-02-27PFIZER INC.$3,500Research paymentCash or cash equivalentAN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL 2024
2024-02-27PFIZER INC.$1,576Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2024
2024-02-22ABBVIE INC.$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentSKYRIZI Biological, IMMUNOLOGY2024
2024-02-21Impulse Dynamics (USA) Inc.$3,432Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DevicePost Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy2024
2024-02-21Impulse Dynamics (USA) Inc.$220Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DeviceAssessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer)2024
2024-02-16PFIZER INC.$9,100Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-02-15Penumbra, Inc.$1,490Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2024
2024-02-14Endologix LLC$1,950Research paymentCash or cash equivalentENDOCROSS Device Device, Cardiology/Vascular DiseasesDetour II Study2024
2024-02-12Impulse Dynamics (USA) Inc.$4,250Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DevicePost Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy2024
2024-02-12Impulse Dynamics (USA) Inc.$3,264Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DevicePost Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy2024
2024-02-09PFIZER INC.$20,944Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2024
2024-02-08PFIZER INC.$12,500Research paymentCash or cash equivalentAN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL 2024
2024-02-06PFIZER INC.$7,265Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2024
2024-02-06PFIZER INC.$6,319Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-02-01Medtronic, Inc.$600Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2024
2024-02-01Medtronic, Inc.$600Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2024
2024-01-31Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-01-31Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-01-26PFIZER INC.$39,634Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2024
2024-01-26PFIZER INC.$13,296Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-01-26PFIZER INC.$5,675Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO2024
2024-01-25Medtronic, Inc.$600Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2024
2024-01-25Medtronic, Inc.$600Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2024
2024-01-23Impulse Dynamics (USA) Inc.$300Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DeviceAssessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer)2024
2024-01-21Medtronic, Inc.$250Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2024
2024-01-21Medtronic, Inc.$250Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2024
2024-01-19Medtronic, Inc.$5,833Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-01-19Medtronic, Inc.$5,833Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-01-19Medtronic, Inc.$2,208Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2024
2024-01-19Medtronic, Inc.$2,208Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2024
2024-01-18Medtronic, Inc.$892Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2024
2024-01-18Medtronic, Inc.$892Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2024
2024-01-17Genentech, Inc.$10,822Research paymentCash or cash equivalentMorningSun2024
2024-01-17Genentech, Inc.$2,760Research paymentCash or cash equivalentMorningSun2024
2024-01-17Genentech, Inc.$2,070Research paymentCash or cash equivalentMorningSun2024
2024-01-17AngioDynamics, Inc.$577Long term medical supply or device loanIn-kind items and servicesSolero Device, Oncology2024
2024-01-17Medtronic, Inc.$280Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2024
2024-01-17Medtronic, Inc.$280Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2024
2024-01-10PFIZER INC.$900Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2024
2024-01-06PFIZER INC.$6,862Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-01-06PFIZER INC.$5,983Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2024
2024-01-03Eli Lilly and Company$15,050Research paymentCash or cash equivalentSTUDY OF LOXO-305 VERSUS INVESTIGATOR'S CHOICE (IDELAR OR BR) IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LE2024

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Wayne CountyDetroit city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Detroit, MI, county Wayne County, MI, state Michigan; placed by its city name.

MeasurePlace (city or town)
Detroit, MI
County
Wayne County, MI
State
Michigan
Population B01003638,5301,772,25910,077,761
Population, 2020 census P1639,1111,793,56110,077,331
Median age B0100235.237.940.2
Under 18 B0100124.8%23.6%21.2%
65 and over B0100115.1%16.6%18.6%
Households B11001257,998700,5914,076,369
Foreign born B050026.6%10.3%7.2%
Median household income B19013$39,938$60,539$72,875
Median family income B19113$49,398$79,522$93,357
Per capita income B19301$24,594$34,906$40,735
Poverty rate B1700132.7%20.8%13.2%
Unemployment rate B2302514.0%8.7%5.7%
Civilian labor force B23025268,955828,8385,018,449
Mean commute (minutes) B0801324.824.724.2
Bachelor's degree or higher B1500318.1%27.6%32.4%
Housing units B25001329,393801,0834,622,236
Owner-occupied B2500350.3%64.8%73.2%
Renters B2500349.7%35.2%26.8%
Median home value B25077$83,900$178,500$231,600
Median gross rent B25064$1,074$1,132$1,129
White, not Hispanic B0300210.8%47.9%72.4%
Black B0300275.0%36.6%13.1%
Hispanic or Latino B030028.3%6.9%5.9%
Asian B030021.7%3.7%3.4%
American Indian and Alaska Native B030020.2%0.2%0.3%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Detroit, MI.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.